Novo’s Sales Woes Herald Danish Export Slowdown, Watchdog Says

Denmark’s exports will grow clearly less than expected earlier, partly due to the setbacks Novo Nordisk A/S is facing in the US, the state’s fiscal watchdog forecast.

The Nordic nation’s economy has thrived on the success of the maker of obesity treatments, with the job market as well as public finances boosted in recent years as Novo became one of the world’s largest drug firms. However, Denmark is now also exposed to the flip side of the linkage as fluctuations of medicine sales make it difficult for forecasters to predict economic developments.